GI
RNAC icon

GAMMA Investing’s Cartesian Therapeutics RNAC Stock Holding History

GAMMA Investing’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14K Sell
205
-607
-75% -$4.5K ﹤0.01% 3722
2026
Q1 		$4.99K Buy
+812
New +$5.79K ﹤0.01% 3360
2025
Q4 		– Sell
-15
Closed -$153 – 4129
2025
Q3 		$153 Hold
15
– – ﹤0.01% 3813
2025
Q2 		$156 Buy
15
+6
+67% +$64 ﹤0.01% 3734
2025
Q1 		$119 Buy
+9
New +$161 ﹤0.01% 3777

Other funds holding RNAC

FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.84B AUM 28.81% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

GAMMA Investing's RNAC Position: Q2 2026 in Review

GAMMA Investing reduced its Cartesian Therapeutics (RNAC) stake by 75% in Q2 2026, selling an estimated $4.5K and leaving 205 shares worth $2.14K. The position accounts for ﹤0.01% of the portfolio, ranked #3722.

GAMMA Investing first reported a position in RNAC in Q1 2025 and has held it in 5 quarters since. The position peaked at $4.99K in Q1 2026. 17 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • GAMMA Investing held 205 shares of Cartesian Therapeutics worth $2.14K as of Q2 2026.
  • GAMMA Investing sold 607 Cartesian Therapeutics shares in Q2 2026, an estimated $4.5K.
  • Cartesian Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3722 holding.
  • GAMMA Investing first reported a position in Cartesian Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • GAMMA Investing's Cartesian Therapeutics position peaked at $4.99K in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.